InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced the Company will be presenting at.
Vancouver, British Columbia (Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Epidermolysis Bullosa Therapeutics Market to Grow to USD 11 3 Billion by 2033: CAGR 12 40% | Marketr pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 114,500 shares, a growth of 1,011.7% from the March 31st total of 10,300 shares. Based on an average daily volume of 350,700 shares, the days-to-cover ratio is currently 0.3 […]